Loading…
Vaccine biotech developing next-generation pneumococcal conjugate vaccines using a proprietary cell-free protein synthesis platform.
Vaccine biotech developing next-generation pneumococcal conjugate vaccines using a proprietary cell-free protein synthesis platform.
Has no product sales yet; the business is research and clinical trials funded by selling shares to investors, so progress is judged by trial data. If approved, its vaccines would be sold as routine immunizations paid for by insurers and government programs, competing with entrenched products.
Moat: narrow (IP / patents, process know-how). A proprietary cell-free manufacturing platform enables higher-valency vaccines than incumbents, patent-protected.
Headquarters: Foster City, California, US · Founded: 2013 · Employees: 507
Size Vaxcyte (PCVX) is a United States Health Care company (Biotechnology) with a market value of $10.1B, the 774th largest of 3,117 United States companies the cockpit tracks. Shares closed at $63.89 on 6 Nov 2026.
Performance Over six months the shares gained 20.5%, against +9.7% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.
Capital Return on invested capital runs 77.7 points below its cost of capital (11.3% WACC).
Credit Vaxcyte has 1 bond outstanding ($575M).
Short interest Short interest is 9.3% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$26.8M | -$24.9M | -$15.8M | -$10.2M | -$9.20M |
| EBITDA | -$1.14B | -$899M | -$554M | -$383M | -$200M |
| Net income | -$1.06B | -$767M | -$464M | -$402M | -$223M |
| Free cash flow | -$921M | -$713M | -$572M | -$365M | -$176M |
| Capital expenditure | $39.8M | $57.0M | $119M | $67.9M | $5.85M |
| Total debt | $115M | $117M | $71.1M | $29.2M | $17.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Vaxcyte PCVX | $10.1B | +21% | n/a | n/a | n/a | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| GSK GSK.L | $102B | 0% | +4% | 25% | 2.9× | -0.1% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 2.6× | -5.4% |
| SKBS 302440.KS | $2.22B | -11% | +23% | -25% | 4.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PCVX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -4.6% | 10th highest of 21 |
| 6-month return | +20.5% | +9.7% | 10th highest of 21 |
| Distance from 52-week high | -29.6% | -22.0% | 10th lowest of 21 |
| ROIC minus cost of capital | -77.7 pp | -1.1 pp | 2nd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% | +26.0% |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% | +0.1% |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| Elanco Animal Health ELAN | United States | $12.9B | +9% | +12% | 7% | 3.2× | 34.8% | +7.6% |
| Summit Therapeutics SMMT | United States | $13.1B | -10% | n/a | n/a | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | 18.3× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
Vaxcyte has 1 bond outstanding with $575M face value.